Relationship between TP53 gene mutation and overall survival time of myelodysplastic syndromes: a Meta-analysis

VernacularTitle:TP53基因突变与骨髓增生异常综合征总生存时间关系的Meta分析
Author: Yan SUN ¹ ; Haiyan XIAO ; Mingjing WANG ; Yumeng LI ; Teng FAN ; Xueying WANG ; Weiyi LIU ; Xiaomei HU
Author Information

1. 北京中医药大学研究生院　100029
From: Journal of Leukemia & Lymphoma 2020;29(6):361-365
CountryChina
Language:Chinese
Abstract: Objective:To investigate the relationship between TP53 gene mutation and overall survival (OS) time of myelodysplastic syndrome (MDS).Methods:Databases, including PubMed, Cochrane Library and Embase were searched for relevant studies published up to 20 October, 2019. The corresponding hazard ratio ( HR) and their 95% confidence interval ( CI) for OS from multivariate Cox proportional hazard models were extracted. The combined HR with their 95% CI was calculated by using fixed or random effect models. Meta-analysis was performed by using Revman 5.3 software. Results:A total of 1 033 patients from 6 studies were enrolled. Meta-analysis results showed that OS time in TP53 gene mutation group was shorter than that in wild type group for patients with MDS ( HR = 2.16, 95% CI 1.52-3.07, P < 0.01). The prognostic risk for post-transplantation patients with MDS ( HR = 2.69, 95% CI 1.63-4.43, P < 0.01) was lower compared with that for patients treated by azacitidine( HR = 2.89, 95% CI 1.37-6.08, P = 0.005). Conclusion:TP53 gene mutation is a risk factor affecting OS of MDS patients.